{"entity":{"id":"nct07022002","kind":"trial","name":"SSGJ-705 Monotherapy and Combination Therapy in Advanced HER2-Expressing Solid Tumors","aka":[],"tldr":"A phase 2 trial of SSGJ-705 in advanced solid tumours, run by Shenyang Sunshine Pharmaceutical Co., LTD., now recruiting.","summary":"SSGJ-705 Monotherapy and Combination Therapy in Advanced HER2-Expressing Solid Tumors is a phase 2 interventional study registered as NCT07022002 by Shenyang Sunshine Pharmaceutical Co., LTD., with 340 participants planned, started 2025-07-30 and due to reach its primary completion in 2026-12-31. Interventions recorded: SSGJ-705, PD-1/L1 inhibitor combined with chemotherapy and SSGJ-705 combined with chemotherapy.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07022002","url":"https://clinicaltrials.gov/study/NCT07022002"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["ssgj-705"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07022002","phase":"2","setting":"A Phase II Study to Evaluate the Safety and Efficacy of SSGJ-705 Monotherapy and Combination Therapy in Patients With Advanced HER2-Expressing Solid Tumors","sponsor":"Shenyang Sunshine Pharmaceutical Co., LTD.","enrolled":340,"outcomes":[]},"route":"/trials/nct07022002/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"ssgj-705","kind":"drug","name":"SSGJ-705","route":"/drugs/ssgj-705/"}]}}